

Richard F Riedel

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/197300/publications.pdf>

Version: 2024-02-01

94
papers

7,415
citations

126907

33
h-index

56724

83
g-index

98
all docs

98
docs citations

98
times ranked

9290
citing authors

#	ARTICLE	IF	CITATIONS
1	NCCN Task Force Report: Update on the Management of Patients with Gastrointestinal Stromal Tumors. Journal of the National Comprehensive Cancer Network: JNCCN, 2010, 8, S-1-S-41.	4.9	1,004
2	Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial. Lancet Oncology, The, 2017, 18, 1493-1501.	10.7	921
3	Comprehensive and Integrated Genomic Characterization of Adult Soft Tissue Sarcomas. Cell, 2017, 171, 950-965.e28.	28.9	738
4	Genomic signatures to guide the use of chemotherapeutics. Nature Medicine, 2006, 12, 1294-1300.	30.7	557
5	Soft Tissue Sarcoma, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2018, 16, 536-563.	4.9	457
6	Sorafenib for Advanced and Refractory Desmoid Tumors. New England Journal of Medicine, 2018, 379, 2417-2428.	27.0	287
7	Soft Tissue Sarcoma, Version 2.2016, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2016, 14, 758-786.	4.9	239
8	A mouse-human phase 1 co-clinical trial of a protease-activated fluorescent probe for imaging cancer. Science Translational Medicine, 2016, 8, 320ra4.	12.4	224
9	Doxorubicin plus evofosfamide versus doxorubicin alone in locally advanced, unresectable or metastatic soft-tissue sarcoma (TH CR-406/SARC021): an international, multicentre, open-label, randomised phase 3 trial. Lancet Oncology, The, 2017, 18, 1089-1103.	10.7	214
10	Results of an International Randomized Phase III Trial of the Mammalian Target of Rapamycin Inhibitor Ridaforolimus Versus Placebo to Control Metastatic Sarcomas in Patients After Benefit From Prior Chemotherapy. Journal of Clinical Oncology, 2013, 31, 2485-2492.	1.6	213
11	NCCN Guidelines Insights: Soft Tissue Sarcoma, Version 1.2021. Journal of the National Comprehensive Cancer Network: JNCCN, 2020, 18, 1604-1612.	4.9	175
12	Randomized Double-Blind Phase II Study of Regorafenib in Patients With Metastatic Osteosarcoma. Journal of Clinical Oncology, 2019, 37, 1424-1431.	1.6	172
13	The Clinical Management of Chondrosarcoma. Current Treatment Options in Oncology, 2009, 10, 94-106.	3.0	120
14	Effects of enhanced caregiver training program on cancer caregiver's self-efficacy, preparedness, and psychological well-being. Supportive Care in Cancer, 2016, 24, 327-336.	2.2	118
15	Soft Tissue Sarcoma, Version 2.2012. Journal of the National Comprehensive Cancer Network: JNCCN, 2012, 10, 951-960.	4.9	117
16	Correlative Analyses of the SARC028 Trial Reveal an Association Between Sarcoma-Associated Immune Infiltrate and Response to Pembrolizumab. Clinical Cancer Research, 2020, 26, 1258-1266.	7.0	115
17	Soft Tissue Sarcoma. Journal of the National Comprehensive Cancer Network: JNCCN, 2010, 8, 630-674.	4.9	112
18	Pharmacogenomic Strategies Provide a Rational Approach to the Treatment of Cisplatin-Resistant Patients With Advanced Cancer. Journal of Clinical Oncology, 2007, 25, 4350-4357.	1.6	98

#	ARTICLE	IF	CITATIONS
19	Gastrointestinal Stromal Tumors, Version 2.2014. Journal of the National Comprehensive Cancer Network: JNCCN, 2014, 12, 853-862.	4.9	96
20	Expression of Constitutively Active Raf-1 in the Mitochondria Restores Antiapoptotic and Leukemogenic Potential of a Transformation-deficient BCR/ABL Mutant. Journal of Experimental Medicine, 1998, 187, 1995-2007.	8.5	94
21	Soft Tissue Sarcoma, Version 2.2014. Journal of the National Comprehensive Cancer Network: JNCCN, 2014, 12, 473-483.	4.9	84
22	Cross Species Genomic Analysis Identifies a Mouse Model as Undifferentiated Pleomorphic Sarcoma/Malignant Fibrous Histiocytoma. PLoS ONE, 2009, 4, e8075.	2.5	71
23	Sirolimus for Patients With Malignant Perivascular Epithelioid Cell Tumors. Journal of Clinical Oncology, 2021, 39, 3660-3670.	1.6	69
24	Clinical activity of pembrolizumab (P) in undifferentiated pleomorphic sarcoma (UPS) and dedifferentiated/pleomorphic liposarcoma (LPS): Final results of SARC028 expansion cohorts.. Journal of Clinical Oncology, 2019, 37, 11015-11015.	1.6	65
25	A genomic approach to identify molecular pathways associated with chemotherapy resistance. Molecular Cancer Therapeutics, 2008, 7, 3141-3149.	4.1	64
26	Thymoma: Benign Appearance, Malignant Potential. Oncologist, 2006, 11, 887-894.	3.7	62
27	Characterizing the developmental pathways TTF-1 , NKX2-8 , and PAX9 in lung cancer. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 5312-5317.	7.1	50
28	A phase I study of bevacizumab, everolimus and panitumumab in advanced solid tumors. Cancer Chemotherapy and Pharmacology, 2012, 70, 95-102.	2.3	40
29	Rationale and emerging strategies for immune checkpoint blockade in soft tissue sarcoma. Cancer, 2018, 124, 3819-3829.	4.1	39
30	Safety and efficacy of PD-1 blockade using pembrolizumab in patients with advanced soft tissue (STS) and bone sarcomas (BS): Results of SARC028 A multicenter phase II study.. Journal of Clinical Oncology, 2016, 34, 11006-11006.	1.6	37
31	Systemic Anti-Cancer Therapy in Synovial Sarcoma: A Systematic Review. Cancers, 2018, 10, 417.	3.7	36
32	Phase II study of atezolizumab in advanced alveolar soft part sarcoma (ASPS).. Journal of Clinical Oncology, 2021, 39, 11519-11519.	1.6	36
33	Impact of a multidisciplinary thoracic oncology clinic on the timeliness of care. Journal of Thoracic Oncology, 2006, 1, 692-6.	1.1	34
34	Systemic therapy for advanced soft tissue sarcomas. Cancer, 2012, 118, 1474-1485.	4.1	33
35	Multicenter phase II study of pembrolizumab (P) in advanced soft tissue (STS) and bone sarcomas (BS): Final results of SARC028 and biomarker analyses.. Journal of Clinical Oncology, 2017, 35, 11008-11008.	1.6	32
36	A phase II trial of regorafenib (REGO) in patients (pts) with advanced Ewing sarcoma and related tumors (EWS) of soft tissue and bone: SARC024 trial results.. Journal of Clinical Oncology, 2017, 35, 11005-11005.	1.6	30

#	ARTICLE	IF	CITATIONS
37	Dose-escalation study of a second-generation non-ansamycin HSP90 inhibitor, onalespib (AT13387), in combination with imatinib in patients with metastatic gastrointestinal stromal tumour. <i>European Journal of Cancer</i> , 2016, 61, 94-101.	2.8	25
38	Improvements in Patient and Health System Outcomes Using an Integrated Oncology and Palliative Medicine Approach on a Solid Tumor Inpatient Service. <i>Journal of Oncology Practice</i> , 2017, 13, e738-e748.	2.5	25
39	Recent advances in the understanding and management of liposarcoma. <i>Faculty Reviews</i> , 2021, 10, 1.	3.9	24
40	Phase II Randomized Study of CMB305 and Atezolizumab Compared With Atezolizumab Alone in Soft-Tissue Sarcomas Expressing NY-ESO-1. <i>Journal of Clinical Oncology</i> , 2022, 40, 1291-1300.	1.6	24
41	A Phase 1b Dose Escalation Trial of NC-6300 (Nanoparticle Epirubicin) in Patients with Advanced Solid Tumors or Advanced, Metastatic, or Unresectable Soft-tissue Sarcoma. <i>Clinical Cancer Research</i> , 2020, 26, 4225-4232.	7.0	22
42	Optimal Avapritinib Treatment Strategies for Patients with Metastatic or Unresectable Gastrointestinal Stromal Tumors. <i>Oncologist</i> , 2021, 26, e622-e631.	3.7	20
43	ABI-009 (<i>sirolimus</i>) in advanced malignant perivascular epithelioid cell tumors (PEComa): Preliminary efficacy, safety, and mutational status from AMPECT, an open label phase II registration trial.. <i>Journal of Clinical Oncology</i> , 2019, 37, 11005-11005.	1.6	20
44	Targeted Agents for Sarcoma: Is Individualized Therapy Possible in Such a Diverse Tumor Type?. <i>Seminars in Oncology</i> , 2011, 38, S30-S42.	2.2	19
45	A Phase I Trial of the IGF-1R Antibody Ganitumab (AMG 479) in Combination with Everolimus (RAD001) and Panitumumab in Patients with Advanced Cancer. <i>Oncologist</i> , 2018, 23, 782-790.	3.7	19
46	SU2C-SARC032: A phase II randomized controlled trial of neoadjuvant pembrolizumab with radiotherapy and adjuvant pembrolizumab for high-risk soft tissue sarcoma.. <i>Journal of Clinical Oncology</i> , 2018, 36, TPS11588-TPS11588.	1.6	16
47	Evolving strategies for management of desmoid tumor. <i>Cancer</i> , 2022, 128, 3027-3040.	4.1	16
48	A phase 1B/ phase 2A study of TRC105 (Endoglin Antibody) in combination with pazopanib (P) in patients (pts) with advanced soft tissue sarcoma (STS).. <i>Journal of Clinical Oncology</i> , 2016, 34, 11016-11016.	1.6	15
49	Phase 2 results of selinexor in advanced de-differentiated (DDLs) liposarcoma (SEAL) study: A phase 2/3, randomized, double blind, placebo controlled cross-over study.. <i>Journal of Clinical Oncology</i> , 2018, 36, 11512-11512.	1.6	15
50	Selinexor in Advanced, Metastatic Dedifferentiated Liposarcoma: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial. <i>Journal of Clinical Oncology</i> , 2022, 40, 2479-2490.	1.6	15
51	Long-term follow-up for duration of response (DoR) after weekly <i>sirolimus</i> in patients with advanced malignant perivascular epithelioid cell tumors (PEComa): Results from a registrational open-label phase II trial, AMPECT.. <i>Journal of Clinical Oncology</i> , 2020, 38, 11516-11516.	1.6	14
52	A Randomized, Double-Blind, Placebo-Controlled, Phase II Study of Regorafenib Versus Placebo in Advanced/Metastatic, Treatment-Refractory Liposarcoma: Results from the SARC024 Study. <i>Oncologist</i> , 2020, 25, e1655-e1662.	3.7	13
53	TK216 for relapsed/refractory Ewing sarcoma: Interim phase 1/2 results.. <i>Journal of Clinical Oncology</i> , 2021, 39, 11500-11500.	1.6	13
54	Primary Meningeal Rhabdomyosarcoma. <i>Sarcoma</i> , 2011, 2011, 1-4.	1.3	12

#	ARTICLE	IF	CITATIONS
55	Pathologic Complete Response of a Malignant Peripheral Nerve Sheath Tumor in the Lung Treated With Neoadjuvant Ifosfamide and Radiation Therapy. <i>Journal of Clinical Oncology</i> , 2012, 30, e291-e293.	1.6	12
56	SARC 028: A phase II study of the anti-PD1 antibody pembrolizumab (P) in patients (Pts) with advanced sarcomas.. <i>Journal of Clinical Oncology</i> , 2015, 33, TPS10578-TPS10578.	1.6	12
57	Small-cell lung cancer: a review of clinical trials. <i>Seminars in Thoracic and Cardiovascular Surgery</i> , 2003, 15, 448-456.	0.6	11
58	Recurrent Extradural Myxopapillary Ependymoma With Oligometastatic Spread. <i>Frontiers in Oncology</i> , 2019, 9, 1322.	2.8	11
59	Health-related quality of life and pain with selinexor in patients with advanced dedifferentiated liposarcoma. <i>Future Oncology</i> , 2021, 17, 2923-2939.	2.4	10
60	A phase II randomized study of CMB305 and atezolizumab versus atezolizumab in NY-ESO-1⁺ soft tissue sarcoma: Analysis of immunogenicity, tumor control, and patient survival.. <i>Journal of Clinical Oncology</i> , 2019, 37, 11011-11011.	1.6	10
61	A Phase II Trial of Carboplatin/Vinorelbine with Pegfilgrastim Support for the Treatment of Patients with Advanced Non-small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2007, 2, 520-525.	1.1	9
62	The experiences of older caregivers of cancer patients following hospital discharge. <i>Supportive Care in Cancer</i> , 2019, 27, 609-616.	2.2	9
63	Phase I study of pazopanib plus TH-302 in advanced solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2017, 79, 611-619.	2.3	8
64	Phase III, placebo-controlled trial (SUCCEED) evaluating ridaforolimus as maintenance therapy in advanced sarcoma patients following clinical benefit from prior standard cytotoxic chemotherapy: Long-term (≈¥ 24 months) overall survival results.. <i>Journal of Clinical Oncology</i> , 2012, 30, 10010-10010.	1.6	8
65	Early palliative care on an inpatient oncology unit: Impact of a novel co-rounding partnership on patient and health system outcomes.. <i>Journal of Clinical Oncology</i> , 2014, 32, 3-3.	1.6	8
66	Dual-Energy CT Vital Iodine Tumor Burden for Response Assessment in Patients With Metastatic GIST Undergoing TKI Therapy: Comparison With Standard CT and FDG PET/CT Criteria. <i>American Journal of Roentgenology</i> , 2022, 218, 659-669.	2.2	8
67	Epidermal growth factor receptor mutations predict sensitivity to gefitinib in patients with non-small-cell lung cancer. <i>Future Oncology</i> , 2005, 1, 461-466.	2.4	6
68	Rhabdomyosarcomatous Transformation of a Gastrointestinal Stromal Tumor following Treatment with Imatinib. <i>Case Reports in Oncological Medicine</i> , 2015, 2015, 1-5.	0.3	6
69	P10015/SARC033: A phase 2 trial of trametinib in patients with advanced epithelioid hemangioendothelioma (EHE).. <i>Journal of Clinical Oncology</i> , 2021, 39, 11503-11503.	1.6	6
70	Assessing the Impact of a Novel Integrated Palliative Care and Medical Oncology Inpatient Service on Health Care Utilization before Hospice Enrollment. <i>Journal of Palliative Medicine</i> , 2019, 22, 420-423.	1.1	5
71	Individualizing systemic therapy for advanced soft tissue sarcomas based on tumor histology and biology. <i>Expert Review of Anticancer Therapy</i> , 2020, 20, 5-8.	2.4	5
72	Large scale multiomic analysis suggests mechanisms of resistance to immunotherapy in leiomyosarcoma.. <i>Journal of Clinical Oncology</i> , 2021, 39, 11512-11512.	1.6	5

#	ARTICLE	IF	CITATIONS
73	Identified Enrollment Challenges of Adolescent and Young Adult Patients on the Nonchemotherapy Arm of Children's Oncology Group Study ARST1321. <i>Journal of Adolescent and Young Adult Oncology</i> , 2021, , .	1.3	5
74	A randomized phase II study of MLN0128 (M) versus pazopanib (P) in patients (pt) with advanced sarcoma (Alliance A091304).. <i>Journal of Clinical Oncology</i> , 2020, 38, 11562-11562.	1.6	4
75	Emerging Therapeutic Targets for Soft Tissue Sarcoma. <i>Current Oncology Reports</i> , 2011, 13, 350-358.	4.0	3
76	Academic-Practice Partnership for Caregiver Training and Support. <i>North Carolina Medical Journal</i> , 2020, 81, 221-227.	0.2	3
77	A phase I study of the safety and activation of a cathepsin-activatable fluorescent cancer-specific probe LUM015.. <i>Journal of Clinical Oncology</i> , 2014, 32, TPS11135-TPS11135.	1.6	3
78	A phase Ib dose-escalation study of TRC105 (anti-endoglin antibody) in combination with pazopanib in patients with advanced soft tissue sarcoma (STS).. <i>Journal of Clinical Oncology</i> , 2015, 33, 10514-10514.	1.6	3
79	Correlation of circulating PD-L2 levels with outcomes of therapy with the anti-PD-1 antibody pembrolizumab (P) in patients (pts) with advanced soft tissue sarcomas (STS): Biomarker analysis of SARC028.. <i>Journal of Clinical Oncology</i> , 2017, 35, 60-60.	1.6	3
80	A randomized, double-blind, placebo-controlled, phase II study of regorafenib vs placebo in advanced/metastatic, treatment-refractory liposarcoma: results from the SARC024 study.. <i>Journal of Clinical Oncology</i> , 2018, 36, 11505-11505.	1.6	3
81	Targeted Therapy in Sarcoma: Should We Be Lumpers or Splitters?. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2012, , 652-657.	3.8	2
82	Anti-angiogenic therapy for malignant solitary fibrous tumour: validation through collaboration. <i>Lancet Oncology</i> , The, 2019, 20, 14-15.	10.7	2
83	Multiomic analysis to reveal distinct molecular profiles of uterine and nonuterine leiomyosarcoma.. <i>Journal of Clinical Oncology</i> , 2021, 39, 11555-11555.	1.6	2
84	The Selinexor in Advanced Liposarcoma (SEAL) study: A phase 2/3, multicenter, randomized, double blind study of selinexor versus placebo in patients with advanced, unresectable, dedifferentiated liposarcoma (DDLs).. <i>Journal of Clinical Oncology</i> , 2016, 34, TPS11072-TPS11072.	1.6	2
85	<i>nab</i>-Sirolimus for patients with advanced malignant PEComa with or without prior mTOR inhibitors: Biomarker results from AMPECT and an expanded access program.. <i>Journal of Clinical Oncology</i> , 2022, 40, 11574-11574.	1.6	2
86	Results of NC-6300 (nanoparticle epirubicin) in an expansion cohort of patients with angiosarcoma.. <i>Journal of Clinical Oncology</i> , 2021, 39, 11543-11543.	1.6	1
87	Oncologistsâ€™ perceptions of rounding alongside palliative care physicians: Results of a post-intervention survey study.. <i>Journal of Clinical Oncology</i> , 2013, 31, e20674-e20674.	1.6	1
88	Healthcare utilization among cancer patients prior to hospice.. <i>Journal of Clinical Oncology</i> , 2016, 34, 135-135.	1.6	1
89	TAPPAS: An adaptive enrichment phase 3 trial of TRC105 and pazopanib versus pazopanib alone in patients with advanced angiosarcoma.. <i>Journal of Clinical Oncology</i> , 2018, 36, TPS11590-TPS11590.	1.6	1
90	Making progress in a rare disease: emerging therapeutics in soft tissue sarcomas. <i>F1000Research</i> , 2018, 7, 1737.	1.6	1

#	ARTICLE	IF	CITATIONS
91	Defining the characteristics of medical oncology patients requiring inpatient hospital admission.. Journal of Clinical Oncology, 2016, 34, e18023-e18023.	1.6	0
92	Mutational analysis and safety/efficacy in a phase 2 multi-center investigation of ABI-009 (<i>nab</i> -rapamycin) in patients with advanced malignant perivascular epithelioid cell tumors (PEComa).. Journal of Clinical Oncology, 2018, 36, TPS11589-TPS11589.	1.6	0
93	Detection of endoglin-expressing CTCs in patients enrolled in an adaptive enrichment phase 3 trial of TRC105 and pazopanib versus pazopanib alone in patients with advanced angiosarcoma (TAPPAS).. Journal of Clinical Oncology, 2018, 36, e23570-e23570.	1.6	0
94	Enrollment barriers of adolescents and young adults (AYA) on the non-chemotherapy arm of ARST1321.. Journal of Clinical Oncology, 2020, 38, e19214-e19214.	1.6	0